Menu

CME Corner

This activity has expired. CME/CE credit is no longer available and the following content may not be available or may not be up-to-date. For a list of current activities that offer CME/CE credit, click here.

Program Detail

Release Date: October-28-13
Credit Expiration Date: October-28-14

Faculty

Presenter:
Heather Wakelee, MD
Associate Professor
Department of Medicine, Division of Oncology
Stanford University
Stanford Clinical Cancer Center
Stanford, CA

Content Development Committee:
Shirish M. Gadgeel, MD (Course Director)
Associate Professor
Department of Oncology
Karmanos Cancer Institute
Wayne State University
Detroit, MI

David M. Jackman, MD
Assistant Professor, Department of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, MA

Suresh S. Ramalingam, MD
Professor, Hematology and Medical Oncology
Director, Division of Medical Oncology
Emory University
Winship Cancer Institute
Atlanta, GA

Heather Wakelee, MD
Associate Professor
Department of Medicine, Division of Oncology
Stanford University
Stanford Clinical Cancer Center
Stanford, CA

Credit Hours

Physicians: 1.0 AMA PRA Category 1 CreditTM

Medium

Online Presentation

Program Description

THIS PROGRAM WAS ORIGINALLY PRESENTED AS A VISITING FACULTY GRAND ROUNDS SERIES THROUGHOUT THE COUNTRY, BEGINNING ON APRIL 15, 2013. IF YOU HAVE ALREADY RECEIVED CREDIT FOR ATTENDING ONE OF THE LIVE MEETINGS, YOU ARE INELIGIBLE TO RECEIVE CREDIT FOR THIS ENDURING ACTIVITY.

Advanced NSCLC is incurable, and thus the goal of therapy is to give patients the best quality of life for the longest period of time. Recently, treatment for advanced NSCLC has expanded beyond chemotherapy as the cornerstone of treatment to include a new generation of targeted therapies that interfere with the cellular pathways involved in tumor growth, progression, and cell death. The use of molecularly targeted therapies represents a significant advance in the treatment of NSCLC.

However, the gap between optimal management of NSCLC and current clinical practice is widening as many oncologists remain unaware of new and emerging clinical evidence and how best to apply advances to their clinical practice. The goal of this continuing medical education activity is to expand the ability of oncologists to target molecular pathways of tumor progression in NSCLC, ultimately improving outcomes for patients with NSCLC.

Program Developer/Facilitator

Temple University School of Medicine and MCM Education

Target Audience

The activity is intended for medical, radiation and surgical oncologists, pathologists, pulmonologists and other health care professionals interested and involved in the treatment of patients with NSCLC.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Discuss key molecular marker testing processes and procedures.
  2. Apply molecular marker test results in individualizing therapy plans for patients with NSCLC.
  3. Review the emerging therapies for patients with NSCLC.

Disclosures

It is the policy of the Temple University School of Medicine, The Albert J. Finestone, M.D., Office for Continuing Medical Education that the speaker and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). Temple University School of Medicine, Office for Continuing Medical Education has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosure will be made prior to the activity.

PLANNING COMMITTEE DISCLOSURE STATEMENT
Planning committee members have no financial relationships to disclose.

FACULTY DISCLOSURE STATEMENT
The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, Temple University School of Medicine, Temple University Health System or its affiliates. Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each program attendee must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.



FACULTY DISCLOSURES

Shirish M. Gadgeel, MD:
Grants/Researcher Support: Abbott, Astellas, Boehringer Ingelheim, Clovis, Genentech, Pfizer, Immunogen
Consultant: Astellas, Boehringer Ingelheim, Methylgene

David M. Jackman, MD:
Consultant: Foundation Medicine, Genentech, Infinity Pharmaceuticals
Honoraria (non-promotional presentation): Chugai Pharmaceuticals

Suresh S. Ramalingam, MD:
Consultant: Boehringer Ingelheim, Eli Lilly, Teva, Genentech

Heather Wakelee, MD:
Grants/Researcher Support (through Stanford): Agennix, Arqule, Astra Zeneca, Bayer, Celgene, Eli Lilly, Exelixis, Genentech, Novartis, Pfizer, Regeneron

Credit Statements

Credit Provider Contact Information
Temple University
School of Medicine
The Albert J. Finestone, M.D., Office for CME
3500 North Broad Street, Philadelphia, PA 19140
Phone: 215-707-4787
Fax: 215-707-8268


Accreditation Statement: Temple University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor Continuing Medical Education for physicians.

Certification Statement: Temple University School of Medicine designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

There is no fee to participate and receive credit.

Commercial Support Statements

Supported by independent educational grants from Boehringer Ingelheim Inc., Eli Lilly and Company, Genentech BioOncology, and Astellas.

Instructions

Participants must view/listen to the activity in its entirety, successfully complete the post-test, and submit an evaluation to receive continuing education credit. Credit will be awarded for a score of 75% or better, and a statement may be printed immediately after passing the post-test online.

  1. Review the intended audience, learning objectives, and author disclosures.
  2. Study the educational activity, including the question bank.
  3. Once completed, please proceed to the post-activity survey, and post-test.
    Online, choose the best answer to each post-test question.
  4. Computer Requirements: Minimum System Requirements: • Pentium III, 600 MHz or Equivalent Processor • 512 MB of RAM • Windows XP, Vista, or 7 • Mac OS X • 800x600 Monitor Resolution • 16-bit Color • 16 bit Sound Card with Speakers

Certificate Fee

$0.00

Disclaimer

Copyright ©2013. Temple University School of Medicine. All rights reserved.

Presented by Temple University School of Medicine and MCM Education.

The opinions expressed in these educational activities are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, Temple University School of Medicine, Boehringer Ingelheim, Eli Lilly and Company, or Genentech BioOncology. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.